Business Wire

In the age of AI agents, Splio makes prediction the foundation of CRM and launches its AI-first CRM

12.2.2026 09:30:00 CET | Business Wire | Press Release

Share

Splio announces the launch of its AI-first CRM powered by Tinyclues AI. Now integrated at the core of the platform, predictive AI helps brands orchestrate and personalize their communications at scale across every channel (email, SMS, RCS, WhatsApp...). Splio also unveils "Ask My CRM," its new AI agent designed as an intelligent marketing copilot that, plugged into each brand's customer data, makes customer knowledge easier to access, and speeds up day-to-day CRM management, from analysis to actionable recommendations.

Splio made the strategic choice early on to invest in AI, especially with the acquisition of Tinyclues in 2023, to get ahead of rapid changes in the CRM Market. Today, the company runs an AI-first model with 30% of its annual recurring revenue coming from its AI offerings. Companies such as Air France, Fnac Darty, SNCF Connect, Samsung, as well as ETAM, Maisons du Monde, Mademoiselle bio, and Cyrillus in retail, already rely on Tinyclues AI on a daily basis.

"We quickly recognized the value of predictive AI in CRM. Market acceleration, driven first by generative AI and now by the emergence of AI agents, has validated that view. Today, Splio is an AI-first company and aims to generate more than 50% of its revenue from AI, by 2027, through the deployment of Tinyclues AI at the core of its platform,"says Antoine Scialom, Co-CEO of Splio.

By making prediction the heart of its AI-first CRM, the company enables brands to tackle personalization challenges at scale today, while laying the foundations for a CRM designed as the reference interface for an increasingly conversational and agentic customer relationship.

"At the time of the Tinyclues acquisition, predictive AI was not yet at the center of conversations, but it was already being adopted by early adopters like Air France, Samsung, and Fnac Darty. Today, it has become essential to run CRM at the pace of market change. That's why we're integrating it directly into our new platform, to make its use broadly accessible. We felt it was necessary to evolve our AI to prepare brands now for the era of agentic commerce and conversation," says Antoine Parizot, Co-CEO of Splio.

Tinyclues AI at the core of Splio's CRM and an intelligent copilot to assist marketers

Tinyclues AI now underpins the products that make up Splio's CRM, including marketing automation and loyalty, by using prediction to make personalization and orchestration more effective.

Enhanced with generative and agentic capabilities on top of predictive AI, Tinyclues AI is emerging as a key building block for orchestrating customer engagement at scale, and in the future, for making CRM fully compatible with the new journeys enabled by agentic commerce.

"The integration of Tinyclues AI into Splio's marketing automation had a direct impact on our performance starting in Early Access. Predictive audiences enabled us to increase our average conversion rate threefold, while better targeting each campaign. In addition, we observed that for each A/B test campaign, 90% of our revenue is generated by 28% of our base. This has allowed us to focus our actions on the right segments, better prioritize our campaigns, and manage our CRM with greater precision," says Cédric Gourgeon, e-commerce director of Mademoiselle Bio.

Splio also unveils "Ask My CRM," an AI agent that acts as a copilot for marketing teams, providing insights to spot opportunities and context-aware recommendations from their own data. Connected in real time to each brand's database, it doesn't just execute queries, it understands the business context, "speaks CRM," and analyzes all available information. Every day, teams will be able to converse with their agent to diagnose performance drops, identify new campaign opportunities, and generate ready-to-use deliverables (reports, one-pagers, action plans), directly from customer data.

This new milestone is part of Splio's AI roadmap, with the goal of putting CRM back at the center as customer relationships become more conversational.

https://www.splio.com/

View source version on businesswire.com: https://www.businesswire.com/news/home/20260212659975/en/

Contacts

Press contacts
Clémence Rebours – +33 6 60 57 76 43 – c.rebours@nouvelles-graines.com
Sandra Fernandes – sfernandes@splio.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Imagine Dragons to Perform at Abu Dhabi Grand Prix21.5.2026 17:51:00 CEST | Press Release

Ethara, organiser of the Formula 1 Etihad Airways Abu Dhabi Grand Prix, have announced that one of the world’s biggest bands, Imagine Dragons, will headline the Saturday After-Race Concerts at the F1 Season Finale in Abu Dhabi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521214839/en/ Imagine Dragons to perform at Formula 1 Etihad Airways Abu Dhabi Grand Prix (Photo: AETOSWire) The announcement is another landmark moment for the Abu Dhabi Grand Prix, whose thrilling Yasalam presented by e& fan entertainment offering has become synonymous with the F1 Championship finale in Abu Dhabi and is recognised as one of the most compelling sports and entertainment crossovers globally. The global chart-toppers join Lewis Capaldi and Zara Larsson, who are set to kick off a blockbuster line-up of performances on Yas Island on Thursday, 3 December, with more major international artists to be revealed. With their popular top hits, Ima

Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 16:25:00 CEST | Press Release

Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensuring your investment is delivering.” The rapid growth of the residential solar market created a growing population of “orphaned” solar sy

Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press Release

A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio

The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press Release

Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem

Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press Release

Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye